Immunome, Inc. (IMNM) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-62.3%

$7.38

vs $19.59 price

Levered DCF

$7.27

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

31.88

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-8.84×	-2.12×	-1.99×	-0.72×	-6.06×	-5.73×	-7.31×	-1.87×
P/B	2.96×	3.44×	1.77×	1.61×	3.1×	2.37×	-2.17×	-0.58×
P/S	270.32×	68.88×	15.15×	0×	0×	0×	0×	0×
EV / EBITDA	-5.86×	-3.2×	-4.12×	-0.19×	-4.2×	-3.45×	-7.74×	-1.99×
Gross margin	57.4%	100.0%	100.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	-3084.8%	-3382.4%	-781.4%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	-3060.0%	-3240.4%	-761.9%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	14.69×	4.08×	6.63×	3.09×	5.82×	14.12×	1.88×	1.35×
Debt / equity	0.01×	0.03×	0.01×	0.02×	0.01×	0.01×	-0.02×	-0.05×
Interest coverage	0×	0×	0×	-7,380.2×	-2,520.4×	-322.66×	-97.62×	-54.91×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-33.5%	-161.7%	-89.1%	-221.6%	-51.3%	-43.1%	29.6%	31.1%
Return on invested capital	-33.5%	-164.4%	-86.2%	-217.8%	-52.0%	-29.2%	-269.1%	-221.3%
Return on assets	-31.1%	-121.9%	-71.9%	-153.4%	-42.7%	-40.1%	-208.5%	-176.4%
Free cash flow yield	-10.7%	-26.4%	-4.0%	-108.0%	-12.2%	-13.0%	-12.7%	-52.0%
Earnings yield	-11.3%	-47.0%	-50.3%	-137.7%	-16.5%	-18.2%	-13.7%	-53.4%
Enterprise value	$1.2B	$484.2M	$115.3M	$6.8M	$100.6M	$58.7M	$75.3M	$14.3M
Net debt / EBITDA	3.1×	0.92×	3.47×	0.55×	2.04×	2.3×	0.2×	0.06×
Cash conversion cycle (days)	-412	0	8	0	0	-574	-325	-331